Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Combination EGFR Stimulation with Gene Therapy to Treat Duchenne Muscular Dystrophy

EF 2022-23

Résumé
Duchenne muscular dystrophy (DMD) is a severe progressive muscle wasting disease that manifests during early childhood leading to premature death by the third decade of life. The leading cause of death in these patients is respiratory and cardiac failure as a direct result of disease associated muscle weakness. The disease is caused by a lack of dystrophin, a protein which aids in the stabilization of muscle fibers, making muscle vulnerable to injury in its absence. Importantly, the absence of dystrophin results in dysfunctional muscle stem cells, which serve to regenerate damaged muscle tissue. This defect leads to increased self-renewal and a higher abundance of muscle stem cells, but a lower number of functional muscle stem cells going on to form new muscle fibers. Specifically, the muscle cannot regenerate at the continuous rate at which it is undergoing damage and degeneration. To overcome this defect, we have developed a drug aimed to stimulate muscle regeneration. We hypothesize that use of this drug in combination with established gene therapy to replace dystrophin will promote muscle regeneration and have a synergistic effect in attenuating disease progression in DMD. We will treat dystrophic mice with combination therapy following muscle injury and assess regeneration by examining muscle strength, size, and the quality of muscle stem cells. With no current cure and no effective approved treatments for DMD, the development of novel therapeutics is essential. This research will set the stage for the clinical use of a drug that stimulates muscle regeneration as a regenerative biotherapeutic to treat DMD to increase quality of life and overall lifespan.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
490909
Name
Lofaro Stephanie D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Combination EGFR Stimulation with Gene Therapy to Treat Duchenne Muscular Dystrophy
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cell Biology; Cell Signalling; Epidermal Growth Factor Receptor (Egfr); Gene Therapy; Muscular Dystrophy; Myogenesis; Regeneration; Satellite Cell; Skeletcal Muscle; Stem Cell
Abstract
Duchenne muscular dystrophy (DMD) is a severe progressive muscle wasting disease that manifests during early childhood leading to premature death by the third decade of life. The leading cause of death in these patients is respiratory and cardiac failure as a direct result of disease associated muscle weakness. The disease is caused by a lack of dystrophin, a protein which aids in the stabilization of muscle fibers, making muscle vulnerable to injury in its absence. Importantly, the absence of dystrophin results in dysfunctional muscle stem cells, which serve to regenerate damaged muscle tissue. This defect leads to increased self-renewal and a higher abundance of muscle stem cells, but a lower number of functional muscle stem cells going on to form new muscle fibers. Specifically, the muscle cannot regenerate at the continuous rate at which it is undergoing damage and degeneration. To overcome this defect, we have developed a drug aimed to stimulate muscle regeneration. We hypothesize that use of this drug in combination with established gene therapy to replace dystrophin will promote muscle regeneration and have a synergistic effect in attenuating disease progression in DMD. We will treat dystrophic mice with combination therapy following muscle injury and assess regeneration by examining muscle strength, size, and the quality of muscle stem cells. With no current cure and no effective approved treatments for DMD, the development of novel therapeutics is essential. This research will set the stage for the clinical use of a drug that stimulates muscle regeneration as a regenerative biotherapeutic to treat DMD to increase quality of life and overall lifespan.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lofaro, Stephanie D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~